The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions

References

• Lloyd-JonesDAdamsRCarnethonMAmerican Heart Association Statistics Committee and Stroke Statistics SubcommitteeHeart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics SubcommitteeCirculation2009119348048619171871
   PubMed Web of Science ®Google Scholar
• SilverbergDSWexlerDIainaASchwartzDThe role of correction of anaemia in patients with congestive heart failure: a short reviewEur J Heart Fail200810981982318703380
   PubMed Web of Science ®Google Scholar
• AnandISAnemia and chronic heart failureJ Am Coll Cardiol200852750151118687241
   PubMed Web of Science ®Google Scholar
• MitchellJEEmerging role of anemia in heart failureAm J Cardiol2007996B15D20D
   PubMed Web of Science ®Google Scholar
• SilverbergDSWexlerDIainaASchwartzDThe interaction between heart failure and other heart diseases, renal failure, and anemiaSemin Nephrol200626429630616949468
   PubMed Web of Science ®Google Scholar
• TangYDKatzSDAnemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment optionsCirculation2006113202454246116717164
   PubMed Web of Science ®Google Scholar
• LindenfeldJAPrevalence of anemia and the effects on mortality in patients with heart failureAm Heart J2005149339140115864227
   PubMed Web of Science ®Google Scholar
• GroenveldHFJanuzziJLDammanKAnemia and mortality in heart failure patients: a systematic review and meta-analysisJ Am Coll Cardiol2008521081882718755344
   PubMed Web of Science ®Google Scholar
• OwanTEHodgeDOHergesRMJacobsenSJRogerVLRedfieldMMSecular trends in renal dysfunction and outcomes in hospitalized heart failure patientsJ Card Fail200612425726216679257
   PubMed Web of Science ®Google Scholar
• DunlaySMWestonSARedfieldMMKillianJMRogerVLAnemia and heart failure: a community studyAm J Med2008121872673218691487
   PubMed Web of Science ®Google Scholar
• NemethEIron regulation and erythropoiesisCurr Opin Hematol200815316917518391780
   PubMed Web of Science ®Google Scholar
• WestenbrinkBDVisserFWVoorsAAAnaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as wellEur Heart J200728216617117158825
   PubMed Web of Science ®Google Scholar
• OkonkoDOGrzesloAWitkowskiTEffect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trialJ Am Coll Cardiol200851210311218191732
   PubMed Web of Science ®Google Scholar
• NanasJNMatsoukaCKarageorgopoulosDEtiology of anemia in patients with advanced heart failureJ Am Coll Cardiol200648122485248917174186
   PubMed Web of Science ®Google Scholar
• WestenbrinkBDVoorsAAvan VeldhuisenDJIs anemia in chronic heart failure caused by iron deficiency?J Am Coll Cardiol2007492323012302 author reply 230217560297
   PubMed Web of Science ®Google Scholar
• WeissGIron metabolism in the anemia of chronic diseaseBiochim Biophys Acta20091790768269318786614
   PubMed Web of Science ®Google Scholar
• WeissGGoodnoughLTAnemia of chronic diseaseN Engl J Med2005352101011102315758012
   PubMed Web of Science ®Google Scholar
• JankowskaEAvon HaehlingSAnkerSDMacdougallICPonikowskiPIron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectivesEur Heart J20133481682923100285
   PubMed Web of Science ®Google Scholar
• BolgerAPBartlettFRPenstonHSIntravenous iron alone for the treatment of anemia in patients with chronic heart failureJ Am Coll Cardiol20064861225122716979010
   PubMed Web of Science ®Google Scholar
• VolpeMTrittoCTestaUBlood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profilesAm J Cardiol19947454684738059727
   PubMed Web of Science ®Google Scholar
• van der MeerPVoorsAALipsicESmildeTDvan GilstWHvan VeldhuisenDJPrognostic value of plasma erythropoietin on mortality in patients with chronic heart failureJ Am Coll Cardiol2004441636715234408
   PubMed Web of Science ®Google Scholar
• GeorgeJPatalSWexlerDCirculating erythropoietin levels and prognosis in patients with congestive heart failure: comparison with neurohormonal and inflammatory markersArch Intern Med2005165111304130915956012
   PubMedGoogle Scholar
• PalazzuoliAAntonelliGNutiRAnemia in cardio-renal syndrome: clinical impact and pathophysiologic mechanismsHeart Fail Rev201116660360721336549
   PubMed Web of Science ®Google Scholar
• WeissGMeusburgerERadacherGGarimorthKNeyerUMayerGEffect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietinKidney Int200364257257812846752
   PubMed Web of Science ®Google Scholar
• MacdougallICCooperACErythropoietin resistance: the role of inflammation and pro-inflammatory cytokinesNephrol Dial Transplant200217Suppl 11394312386257
   PubMed Web of Science ®Google Scholar
• RauchhausMDoehnerWFrancisDPPlasma cytokine parameters and mortality in patients with chronic heart failureCirculation2000102253060306711120695
   PubMed Web of Science ®Google Scholar
• AbdullaJAbildstromSZChristensenEKoberLTorp-PedersenCA meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunctionEur J Heart Fail20046792793515556055
   PubMed Web of Science ®Google Scholar
• Australia/New Zealand Heart Failure Research Collaborative Groupa (no authors listed)Randomized placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia/New Zealand Heart Failure Research Collaborative GroupLancet199734990493743809033461
   PubMed Web of Science ®Google Scholar
• AndroneASKatzSDLundLHemodilution is common in patients with advanced heart failureCirculation2003107222622912538419
   PubMed Web of Science ®Google Scholar
• AdlbrechtCKommataSHülsmannMChronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body’s red cell volumeEur Heart J200829192343235018701467
   PubMed Web of Science ®Google Scholar
• AbramovDCohenRSKatzSDManciniDMaurerMSComparison of blood volume characteristics in anemic patients with low versus preserved left ventricular ejection fractionsAm J Cardiol200810281069107218929711
   PubMed Web of Science ®Google Scholar
• HutchinsonCGeisslerCAPowellJJBomfordAProton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosisGut20075691291129517344278
   PubMed Web of Science ®Google Scholar
• Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on Blood Component TherapyAnesthesiology19968437327478659805
   PubMed Web of Science ®Google Scholar
• GoodnoughLTBrecherMEKanterMHAuBuchonJPTransfusion medicine. First of two parts – blood transfusionN Engl J Med199934064384479971869
   PubMed Web of Science ®Google Scholar
• ToblliJELombrañaADuartePDi GennaroFIntravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiencyJ Am Coll Cardiol2007501657166517950147
   PubMed Web of Science ®Google Scholar
• CoyneDWKapoianTSukiWDRIVE Study GroupFerric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients’ Response to IV Iron with Elevated Rerritin (DRIVE) StudyJ Am Soc Nephrol200718397598417267740
   PubMed Web of Science ®Google Scholar
• KapoianTO’MaraNBSinghAKFerric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritinJ Am Soc Nephrol200819237237918216316
   PubMed Web of Science ®Google Scholar
• AnkerSDComin ColetJFilippatosGFAIR-HF Trial InvestigatorsFerric carboxymaltose in patients with heart failure and iron deficiencyN Engl J Med2009361252436244819920054
   PubMed Web of Science ®Google Scholar
• Beck-da-SilvaLPiardiDSoderSIRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemiaInt J Cardiol201316843439344223680589
   PubMed Web of Science ®Google Scholar
• SilverbergDSWexlerDBlumMThe use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizationsJ Am Coll Cardiol20003571737174410841219
   PubMed Web of Science ®Google Scholar
• ManciniDMKatzSDLangCCLaMancaJHudaihedAAndroneASEffect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failureCirculation2003107229429912538431
   PubMed Web of Science ®Google Scholar
• PalazzuoliASilverbergDSIovineFEffects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndromeAm Heart J20071544645.e9645.1517892986
   PubMed Web of Science ®Google Scholar
• PonikowskiPAnkerSDSzachniewiczJEffect of darbepoetin alpha on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trialJ Am Coll Cardiol200749775376217306703
   PubMed Web of Science ®Google Scholar
• van VeldhuisenDJDicksteinKCohen-SolalARandomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemiaEur Heart J200728182208221617681958
   PubMed Web of Science ®Google Scholar
• GhaliJKAnandISAbrahamWTStudy of Anemia in Heart Failure Trial (STAMINA-HeFT) GroupRandomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemiaCirculation2008117452653518195176
   PubMed Web of Science ®Google Scholar
• SwedbergKYoungJBAnandISRED-HF Committees; RED-HF InvestigatorsTreatment of anemia with darbepoetin alfa in systolic heart failureN Engl J Med2013368131210121923473338
   PubMed Web of Science ®Google Scholar
• van der MeerPGroenveldHFJanuzziJLJrVan VeldhuisenDJErythropoietin treatment in patients with chronic heart failure: a meta-analysisHeart200995161309131419168472
   PubMed Web of Science ®Google Scholar
• NgoKKotechaDWaltersJAErythropoiesis-stimulating agents for anemia in chronic heart failure patientsCochrane Database Syst Rev20101CD00761320091643
   PubMed Web of Science ®Google Scholar
• TurnerSJKetchTRGandhiSKSaneDCRoutine hematologic clinical tests as prognostic markers in patients with acute coronary syndromesAm Heart J2008155580681618440326
   PubMed Web of Science ®Google Scholar
• KeungYKOwenJIron deficiency and thrombosis: literature reviewClin Appl Thromb Hemost200410438739115497026
   PubMed Web of Science ®Google Scholar
• VaziriNDAnemia and anemia correction: surrogate markers or causes of morbidity in chronic kidney disease?Nat Clin Pract Nephrol20084843644518542121
   PubMedGoogle Scholar
• FranchiniMTargherGMontagnanaMLippiGIron and thrombosisAnn Hematol200887316717318066546
   PubMed Web of Science ®Google Scholar
• DavìGPatronoCPlatelet activation and atherosclerosisN Engl J Med2007357242482249418077812
   PubMed Web of Science ®Google Scholar
• EschbachJWAbdulhadiMHBrowneJKRecombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trialAnn Int Med19891111299210002688507
   PubMed Web of Science ®Google Scholar
• BeguinYLooMR’ZikSEffect of recombinant human erythropoietin on platelets in patients with anemia of renal failure: correlation of platelet count with erythropoietic activity and iron parametersEur J Haematol19945352652707813706
   PubMed Web of Science ®Google Scholar
• StohlawetzPJDzirloLHergovichNEffects of erythropoietin on platelet reactivity and thrombopoiesis in humansBlood20009592983298910779449
   PubMed Web of Science ®Google Scholar
• DahlNVHenryDHCoyneDWThrombosis with erythropoietic stimulating agents-does iron-deficient erythropoiesis play a role?Semin Dial200821321021118397204
   PubMed Web of Science ®Google Scholar
• NagababuEGulyaniSEarleyCJCutlerRGMattsonMPRifkindJMIron-deficiency anaemia enhances red blood cell oxidative stressFree Radic Res200842982482919051108
   PubMed Web of Science ®Google Scholar
• Rozen-ZviBGafter-GviliAPaulMLeiboviciLShpilbergOGafterUIntravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysisAm J Kidney Dis200852589790618845368
   PubMed Web of Science ®Google Scholar
• MaieseKLiFChongZZNew avenues of exploration for erythropoietinJAMA20052931909515632341
   PubMed Web of Science ®Google Scholar
• ArcasoyMOThe non-haematopoietic biological effects of erythropoietinBr J Haematol20081411143118324962
   PubMed Web of Science ®Google Scholar
• RastogiSImaiMSharovVGMishraSSabbahHNDarbepoetin-alpha prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failureAm J Physiol Heart Circ Physiol20082956H2475H248218952719
   PubMed Web of Science ®Google Scholar
• van der MeerPLipsicEHenningRHErythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarctionJ Am Coll Cardiol200546112513315992646
   PubMed Web of Science ®Google Scholar
• AmannKTyrallaKCardiovascular changes in chronic renal failure – pathogenesis and therapyClin Nephrol200258Suppl 1S62S7212227729
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationInformation for Healthcare Professionals Erythropoiesis Stimulating Agents (ESA) FDA Alert [webpage on the Internet]Silver Spring, MDUS Food and Drug Administration2007 Available from: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm126481.htmAccessed July 10, 2014
   Google Scholar
• KDOQINational Kidney FoundationKDOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney diseaseAm J Kidney Dis200647Suppl 5S11S14516678659
   PubMed Web of Science ®Google Scholar
• McMurrayJJAdamopoulosSAnkerSDTask Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of CardiologyESC Committee for Practice GuidelinesESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCEur J Heart Fail201214880386922828712
   PubMed Web of Science ®Google Scholar
• QaseemAHumphreyLLFittermanNStarkeyMShekellePClinical Guidelines Committee of the American College of PhysiciansTreatment of anemia in patients with heart disease: a clinical practice guideline from the American College of PhysiciansAnn Intern Med20131591177077924297193
   PubMed Web of Science ®Google Scholar
• SolomonSDUnoHLewisEFTrial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) InvestigatorsErythropoietic response and outcomes in kidney disease and type 2 diabetesN Engl J Med2010363121146115520843249
   PubMed Web of Science ®Google Scholar